Development and prospective validation of a risk score model in guiding individualized concurrent chemoradiotherapy in stage II nasopharyngeal carcinoma in intensity-modulated radiotherapy era.
Shan-Shan YangYa-Jun PangZhi-Qiang WangBao-Yu ZhangZhi-Qiao LiuEn-Ni ChenPu-Yun OuYangFang-Yun XiePublished in: Cancer medicine (2021)
A risk score model was developed and prospectively validated to precisely select high-risk stage II NPC patients who can benefit from CCRT, and thus guided individualized treatment in IMRT era.